Skip to main content Skip to main navigation menu Skip to site footer

Botulinum toxin type A (BTX-A) to improve the treatment of keloid and hypertrophic scars: A double-blinded randomized clinical trial


Background: Keloid and hypertrophic scars are the results of abnormal skin cells proliferation that usually cause major physical, psychological and cosmetic problems. However, there is no effective method for eliminating this scars yet. Recent reports suggested that BTX-A improves wound healing. However, there is no comprehensive study to assess the efficacy of BTX-A injection for treatment of keloid and hypertrophic scars.

Aim: This study aims to investigate whether BTX-A injection improves the keloid and hypertrophic scars treatment or not.

Methods: Ten patients with keloid or hypertrophic scar lesions were enrolled in this study and randomized into two groups (injected by BTX-A or placebo). Injections were applied at one-month intervals for a total of three months. All the patients were followed up for at least six months. Scars were assessed by mVSS (modified Vancouver Scar Scale) and an independently blinded evaluator with standardized photographs.

Results: The study was completed with ten patients at the six months follow up visits in the treatment group. BTX-A reduced (not significantly, p>0.09) mVSS including pliability, vascularity, pigmentation, and height, but did not affect the pruritis and pain.

Conclusion: It can be concluded in this study that BTX-A can reduce some parameters of mVSS and may be a suitable compound for the treatment of keloid and scar tissue.


  1. Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg. 2000;105(6):1948-53; discussion 54-5.
  2. Gaber MA, Seliet IA, Ehsan NA, Megahed MA. Mast cells and angiogenesis in wound healing. Analytical and quantitative cytopathology and histopathology. 2014;36(1):32-40.
  3. Chun Q, ZhiYong W, Fei S, XiQiao W. Dynamic biological changes in fibroblasts during hypertrophic scar formation and regression. International wound journal. 2016;13(2):257-62.
  4. Atiyeh BS, Costagliola M, Hayek SN. Keloid or hypertrophic scar: the controversy: review of the literature. Annals of plastic surgery. 2005;54(6):676-80.
  5. Berman B, Bieley HC. Keloids. Journal of the American Academy of Dermatology. 1995;33(1):117-23.
  6. Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. Aesthetic plastic surgery. 2009;33(3):409-12.
  7. Verheyden J, Blitzer A. Other noncosmetic uses of BOTOX. Disease-a-Month. 2002;48(5):357-66.
  8. Aarabi S, Longaker MT, Gurtner GC. Hypertrophic scar formation following burns and trauma: new approaches to treatment. PLoS Med. 2007;4(9):e234.
  9. Karsenty G, Rocha J, Chevalier S, Scarlata E, Andrieu C, Zouanat FZ, et al. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo. The Prostate. 2009;69(11):1143-50.
  10. Rohrbach S, Olthoff A, Giefer B, Laskawi R, Götz W. Botulinum toxin type A induces apoptosis in nasal glands of guinea pigs. Annals of Otology, Rhinology & Laryngology. 2001;110(11):1045-50.
  11. Reid RR, Roy N, Mogford JE, Zimmerman H, Lee C, Mustoe TA. Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-β receptor II. Journal of plastic, reconstructive & aesthetic surgery. 2007;60(1):64-72.
  12. Lu L, Saulis AS, Liu WR, Roy NK, Chao JD, Ledbetter S, et al. The temporal effects of anti-TGF-β1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. Journal of the American College of Surgeons. 2005;201(3):391-7.
  13. Xiao Z, Zhang M, Liu Y, Ren L. Botulinum toxin type a inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar. Aesthetic Plast Surg. 2011;35(5):802-7.
  14. Babuccu B, Babuccu O, Yurdakan G, Ankaral H. The effect of the Botulinum toxin-A on craniofacial development: an experimental study. Annals of plastic surgery. 2009;63(4):449-56.
  15. Zimbler MS, Holds JB, Kokoska MS, Glaser DA, Prendiville S, Hollenbeak CS, et al. Effect of botulinum toxin pretreatment on laser resurfacing results: a prospective, randomized, blinded trial. Archives of facial plastic surgery. 2001;3(3):165-9.
  16. Sullivan D, Chung KC, Eaves III FF, Rohrich RJ. The level of evidence pyramid: indicating levels of evidence in Plastic and Reconstructive Surgery articles. Plastic and reconstructive surgery. 2011;128(1):311-4.
  17. Viera MH, Vivas AC, Berman B. Update on Keloid Management: Clinical and Basic Science Advances. Advances in wound care. 2012;1(5):200-6.
  18. Kloeters O, Tandara A, Mustoe TA. Hypertrophic scar model in the rabbit ear: a reproducible model for studying scar tissue behavior with new observations on silicone gel sheeting for scar reduction. Wound Repair and Regeneration. 2007;15(s1):S40-S5.
  19. Carruthers A, Kiene K, Carruthers J. Botulinum A exotoxin use in clinical dermatology. Journal of the American Academy of Dermatology. 1996;34(5):788-97.
  20. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Journal of pediatric ophthalmology and strabismus. 1980;17(1):21-5.
  21. Hallett M. One man's poison—clinical applications of botulinum toxin. Mass Medical Soc; 1999.
  22. Liu A, Moy RL, Ozog DM. Current methods employed in the prevention and minimization of surgical scars. Dermatologic Surgery. 2011;37(12):1740-6.
  23. Zhibo X, Miaobo Z. Potential therapeutical effects of botulinum toxin type A in keloid management. Medical hypotheses. 2008;71(4):623.

How to Cite

Habibi, I., Taheri, A., Hedayatyanfard, K., Farazmand, F., & Habibi, B. (2019). Botulinum toxin type A (BTX-A) to improve the treatment of keloid and hypertrophic scars: A double-blinded randomized clinical trial. Bali Medical Journal, 8(1), 30–34.




Search Panel